OncLive SOSS

Authors

Mark J. Levis, MD, PhD, Johns Hopkins University

Latest:

Combining and Sequencing FLT3 Inhibitors in AML

Harry Erba, MD, PhD; Courtney DiNardo, MD; Mark Levis, MD, PhD; and Vinod Pullarkat, MD, review factors to consider when using combining and/or sequencing first- or second-generation FLT3 inhibitors for patients with acute myeloid leukemia (AML).

Mark J. Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center

Mark J. Mann, MD

Latest:

Dr. Mann on Differences Between Treatments for Prostate Cancer

Mark J. Mann, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the differences between treatment options for patients with prostate cancer subtypes.

Mark J. Roschewski, MD

Latest:

Dr. Roschewski on the Use of DA-EPOCH-R in Burkitt Lymphoma

Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses the use of dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan; DA-EPOCH-R) in patients with Burkitt lymphoma.

Mark J. Truty, MD, MS

Latest:

Dr. Truty on Challenges With Treating Patients With Pancreatic Cancer

Mark J. Truty, MD, MS, assistant professor of surgery, Mayo Clinic, discusses challenges with treating patients with pancreatic cancer.

Mark James Levis, MD, PhD

Latest:

Dr Levis on Maintenance Gilteritinib After ASCT in FLT3-ITD+ AML

Mark J. Levis, MD, PhD, discusses data from the phase 3 BMT CTN 1506/MORPHO trial of gilteritinib as maintenance therapy following allogeneic stem cell transplant in patients With FLT3-ITD–positive acute myeloid leukemia.

Mark Kozloff, MD, Ingalls Cancer Care

Mark Kris, MD, Memorial Sloan-Kettering

Mark Kris, MD, Memorial Sloan Kettering Cancer Center

Mark Levis, MD, PhD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center

Mark M. Zalupski, MD

Latest:

Dr. Zalupski on Implications of the KEYNOTE-061 Trial in Gastric Cancer

Mark M. Zalupski, MD, professor of medicine at the University of Michigan School of Medicine, discusses the clinical implications of the phase III KEYNOTE-061 trial in gastric cancer.

Mark D. Pegram, MD, Stanford Cancer Center

Latest:

Expanding Treatment Options for HER2+ Breast Cancer

Mark R. Gilbert, MD

Latest:

Dr. Gilbert on Precision Medicine in Glioblastoma

Mark R. Gilbert, MD, senior investigator, chief, Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, discusses the use of precision medicine in treating patients with glioblastoma.

Mark R. Litzow, MD

Latest:

Dr. Litzow on New Immunologic Therapies in ALL

Mark R. Litzow, MD, a professor of Medicine in the Division of Hematology at the Mayo Clinic in Rochester, Minnesota, discusses novel immunologic therapies for the treatment of patients with acute lymphoblastic leukemia (ALL).

Mark R. Litzow, MD, Mayo Clinic

Mark R. Litzow, MD, The Mayo Clinic

Mark S. Austenfeld, MD, Kansas City Urology Care

Mark S. Soberman, MD, MBA, FACS

Latest:

Dr. Soberman on Theme of Next-Generation Multidisciplinary Care for Patients With Cancer

Mark S. Soberman, MD, MBA, FACS, the 2017 to 2018 President of the Association of Community Cancer Centers (ACCC), discusses his presidential theme of next-generation multidisciplinary care for patients with cancer.